Mpac Group (MPAC) Fair Value & Analysis
Industrials · GB · Market cap 81.9M GBX
Fair value as of: Jun 24, 2026
Analysis
Mpac Group (MPAC) currently trades at p2.50, while our model-based Fair Value estimate is p2.27 — implying the stock looks roughly 9.2% overvalued today. We read business quality at 95/100 (high quality), in the Industrials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Mpac Group plc, together with its subsidiaries, provides packaging and automation solutions to healthcare, clean energy, and food and beverage sectors worldwide. The company operates through Original Equipment and Service segments. It designs, develops, manufactures, and engineers packaging solutions; and offers automation and secondary packaging equipment, end-of-line robotics with integrated testing solutions, and at line instrumentation solutions. The company offers product assembly, filling and dosing, product handling and infeed, cartoning, case packing, tray forming, and palletising solutions. It offers its products under the Lambert, Langen, Switchback, SIGA Vision, BCA, and CSi Palletising brand names. The company was formerly known as Molins plc and changed its name to Mpac Group plc in January 2018. The company was founded in 1874 and is headquartered in Coventry, the United Kingdom.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Mpac Group (MPAC) undervalued?
What is the fair value of MPAC?
What is the quality score of MPAC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.